Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biovail To Complete Sales Force Reorganization In April; Adds Specialty Reps

This article was originally published in The Pink Sheet Daily

Executive Summary

Increased SG&A expenses associated with the sales force reorganization caused Biovail to miss its 2003 financial guidance. The company expects to out-license tramadol and once-daily metformin.

You may also be interested in...

Biovail Narrows Revenue Guidance; Projected Earnings Remains Unchanged

The company revises its revenue guidance to $820-$920 mil. from $800-$940 mil. Estimate reflects stronger than expected Wellbutrin XL growth as well as lagging Cardizem LA, Teveten and Zovirax sales.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts